Cargando…

Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review

To date, there is no cure or disease-modifying agents available for most well-known neurological disorders. Current therapy is typically focused on relieving symptoms and supportive care in improving the quality of life of affected patients. Furthermore, the traditional de novo drug discovery techni...

Descripción completa

Detalles Bibliográficos
Autores principales: Yimer, Ebrahim M., Hishe, Hailemichael Zeru, Tuem, Kald Beshir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444273/
https://www.ncbi.nlm.nih.gov/pubmed/30971875
http://dx.doi.org/10.3389/fnins.2019.00236
_version_ 1783408002336817152
author Yimer, Ebrahim M.
Hishe, Hailemichael Zeru
Tuem, Kald Beshir
author_facet Yimer, Ebrahim M.
Hishe, Hailemichael Zeru
Tuem, Kald Beshir
author_sort Yimer, Ebrahim M.
collection PubMed
description To date, there is no cure or disease-modifying agents available for most well-known neurological disorders. Current therapy is typically focused on relieving symptoms and supportive care in improving the quality of life of affected patients. Furthermore, the traditional de novo drug discovery technique is more challenging, particularly for neurological disorders. Therefore, the repurposing of existing drugs for these conditions is believed to be an efficient and dynamic approach that can substantially reduce the investments spent on drug development. Currently, there is emerging evidence that suggests the potential effect of a beta-lactam antibiotic, ceftriaxone (CEF), to alleviate the symptoms of different experimentally-induced neurological disorders: Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, epileptic-seizure, brain ischemia, traumatic brain injuries, and neuropathic pain. CEF also affects the markers of oxidative status and neuroinflammation, glutamatergic systems as well as various aggregated toxic proteins involved in the pathogenesis of different neurological disorders. Moreover, it was found that CEF administration to drug dependent animal models improved the withdrawal symptoms upon drug discontinuation. Thus, this review aimed to describe the effects of CEF against multiple models of neurological illnesses, drug dependency, and withdrawal. It also emphasizes the possible mechanisms of neuroprotective actions of CEF with respective neurological maladies.
format Online
Article
Text
id pubmed-6444273
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64442732019-04-10 Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review Yimer, Ebrahim M. Hishe, Hailemichael Zeru Tuem, Kald Beshir Front Neurosci Neuroscience To date, there is no cure or disease-modifying agents available for most well-known neurological disorders. Current therapy is typically focused on relieving symptoms and supportive care in improving the quality of life of affected patients. Furthermore, the traditional de novo drug discovery technique is more challenging, particularly for neurological disorders. Therefore, the repurposing of existing drugs for these conditions is believed to be an efficient and dynamic approach that can substantially reduce the investments spent on drug development. Currently, there is emerging evidence that suggests the potential effect of a beta-lactam antibiotic, ceftriaxone (CEF), to alleviate the symptoms of different experimentally-induced neurological disorders: Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, epileptic-seizure, brain ischemia, traumatic brain injuries, and neuropathic pain. CEF also affects the markers of oxidative status and neuroinflammation, glutamatergic systems as well as various aggregated toxic proteins involved in the pathogenesis of different neurological disorders. Moreover, it was found that CEF administration to drug dependent animal models improved the withdrawal symptoms upon drug discontinuation. Thus, this review aimed to describe the effects of CEF against multiple models of neurological illnesses, drug dependency, and withdrawal. It also emphasizes the possible mechanisms of neuroprotective actions of CEF with respective neurological maladies. Frontiers Media S.A. 2019-03-26 /pmc/articles/PMC6444273/ /pubmed/30971875 http://dx.doi.org/10.3389/fnins.2019.00236 Text en Copyright © 2019 Yimer, Hishe and Tuem. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Yimer, Ebrahim M.
Hishe, Hailemichael Zeru
Tuem, Kald Beshir
Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review
title Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review
title_full Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review
title_fullStr Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review
title_full_unstemmed Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review
title_short Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review
title_sort repurposing of the β-lactam antibiotic, ceftriaxone for neurological disorders: a review
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444273/
https://www.ncbi.nlm.nih.gov/pubmed/30971875
http://dx.doi.org/10.3389/fnins.2019.00236
work_keys_str_mv AT yimerebrahimm repurposingoftheblactamantibioticceftriaxoneforneurologicaldisordersareview
AT hishehailemichaelzeru repurposingoftheblactamantibioticceftriaxoneforneurologicaldisordersareview
AT tuemkaldbeshir repurposingoftheblactamantibioticceftriaxoneforneurologicaldisordersareview